Danaher Corporation $DHR Stock Position Lifted by Van Den Berg Management I Inc.

Van Den Berg Management I Inc. lifted its stake in shares of Danaher Corporation (NYSE:DHR) by 18.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,029 shares of the conglomerate’s stock after purchasing an additional 6,801 shares during the quarter. Danaher comprises about 1.7% of Van Den Berg Management I Inc.’s investment portfolio, making the stock its 21st largest holding. Van Den Berg Management I Inc.’s holdings in Danaher were worth $8,196,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of DHR. Meeder Asset Management Inc. bought a new stake in shares of Danaher during the 2nd quarter worth about $44,000. MidFirst Bank bought a new position in shares of Danaher in the second quarter valued at approximately $46,000. Bell Investment Advisors Inc bought a new position in shares of Danaher in the second quarter valued at approximately $47,000. Fiduciary Financial Advisors acquired a new position in shares of Danaher during the second quarter valued at approximately $53,000. Finally, Solstein Capital LLC bought a new stake in Danaher during the second quarter worth approximately $58,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DHR. TD Cowen decreased their price target on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Evercore reaffirmed an “outperform” rating and set a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. Guggenheim lowered their target price on Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Wells Fargo & Company dropped their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Danaher Price Performance

Shares of NYSE:DHR opened at $216.41 on Friday. The company has a market capitalization of $152.13 billion, a PE ratio of 38.44, a price-to-earnings-growth ratio of 2.69 and a beta of 0.78. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock has a fifty day moving average of $199.46 and a 200-day moving average of $192.52. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the prior year, the business posted $0.77 earnings per share. Danaher’s revenue was up 5.5% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.